The Department of Health (DH), in collaboration with the Guangdong-Hong Kong-Macao Greater Bay Area Center for Medical Device Evaluation and Inspection (GBA Center) of the National Medical Products Administration (NMPA), today (September 15) co-organised the "GBA Medical Device Regulations and Registration Process Training" seminar in Hong Kong. The seminar aims to assist the local trade in tapping into the Chinese Mainland market and to further deepen exchanges and co-operation between the two places in medical device regulation and industry development.

     This was the second seminar of its kind co-organised by the DH and the GBA Center since last May. The Deputy Director of the GBA Center, Mr Xu Liang, and a number of reviewers travelled to Hong Kong to serve as speakers, sharing updates on the GBA Center's latest work and giving an in-depth briefing on the regulatory framework, registration procedures, key market-entry requirements and major review considerations for medical devices in the Chinese Mainland. The seminar helped the trade to gain a comprehensive understanding of the latest trends and market access requirements in the Chinese Mainland.

     The seminar attracted approximately 300 representatives from the local medical device trade, including manufacturers, traders, research and development (R&D) professionals, and regulatory affairs consultants. The participants noted that the training content was substantive and tailored to the industry's practical needs, helping them gain a thorough understanding of the current regulatory regime and the details of the submission arrangements in the Chinese Mainland.

     The DH expresses its gratitude to the NMPA for its support. As the Mainland China is an important global market and R&D hub for medical devices, the DH will continue to organise similar activities to deepen professional exchanges and collaboration. Leveraging Hong Kong's role as a "super connector" and "super value-adder", the DH is committed to promoting healthcare innovation and high-quality development of the industry.
     ​
     At the same time, in line with the nation's strategic initiatives to accelerate the development of "Healthy China" and prioritise health in development, the DH will work toward building "Healthy Hong Kong". Promoting innovation in cross-boundary medical co-operation will not only help Hong Kong integrate into the "Healthy GBA", but will also allow Hong Kong's internationally recognised healthcare system to contribute to elevating national medical standards to the global stage, thereby underscoring Hong Kong's unique advantages and value in integrating into and serving the nation's overall development.

Ends/Tuesday, September 15, 2026
Issued at HKT 17:00

NNNN